5/22/2014 8:08:44 AM
Teva Pharmaceutical Industries Ltd. (TEVA) may be sitting on the edge of a patent cliff, with 21 percent of its revenue at risk. You wouldn’t know it, though, with its stock near a three-year-high. Two reasons: Teva’s legal efforts to block cheaper generic versions of the multiple-sclerosis shot Copaxone, which garnered $4.3 billion in sales last year, and its surprising success in shifting patients to a longer-acting version that won’t face competition until 2030. Teva analysts have raised their estimates for 2014 earnings.
Help employers find you! Check out all the jobs and post your resume.
comments powered by